{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:07:40Z","timestamp":1785863260248,"version":"3.56.0"},"reference-count":53,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T00:00:00Z","timestamp":1460073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Marburg virus (MARV) was the first filovirus to be identified following an outbreak of viral hemorrhagic fever disease in Marburg, Germany in 1967. Due to several factors inherent to filoviruses, they are considered a potential bioweapon that could be disseminated via an aerosol route. Previous studies demonstrated that MARV virus-like particles (VLPs) containing the glycoprotein (GP), matrix protein VP40 and nucleoprotein (NP) generated using a baculovirus\/insect cell expression system could protect macaques from subcutaneous (SQ) challenge with multiple species of marburgviruses. In the current study, the protective efficacy of the MARV VLPs in conjunction with two different adjuvants: QS-21, a saponin derivative, and poly I:C against homologous aerosol challenge was assessed in cynomolgus macaques. Antibody responses against the GP antigen were equivalent in all groups receiving MARV VLPs irrespective of the adjuvant; adjuvant only-vaccinated macaques did not demonstrate appreciable antibody responses. All macaques were subsequently challenged with lethal doses of MARV via aerosol or SQ as a positive control. All MARV VLP-vaccinated macaques survived either aerosol or SQ challenge while animals administered adjuvant only exhibited clinical signs and lesions consistent with MARV disease and were euthanized after meeting the predetermined criteria. Therefore, MARV VLPs induce IgG antibodies recognizing MARV GP and VP40 and protect cynomolgus macaques from an otherwise lethal aerosol exposure with MARV.<\/jats:p>","DOI":"10.3390\/v8040094","type":"journal-article","created":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T21:02:38Z","timestamp":1460149358000},"page":"94","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)"],"prefix":"10.3390","volume":"8","author":[{"given":"John","family":"Dye","sequence":"first","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Warfield","sequence":"additional","affiliation":[{"name":"Integrated Biotherapeutics, Inc., Gaithersburg, MD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wells","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Unfer","sequence":"additional","affiliation":[{"name":"Integrated Biotherapeutics, Inc., Gaithersburg, MD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shulenin","sequence":"additional","affiliation":[{"name":"Integrated Biotherapeutics, Inc., Gaithersburg, MD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Vu","sequence":"additional","affiliation":[{"name":"Integrated Biotherapeutics, Inc., Gaithersburg, MD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Nichols","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aman","sequence":"additional","affiliation":[{"name":"Integrated Biotherapeutics, Inc., Gaithersburg, MD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Bavari","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/v4101878","article-title":"Forty-five years of marburg virus research","volume":"4","author":"Brauburger","year":"2012","journal-title":"Viruses"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Martini, G.A., and Siegert, R. (1971). Marburg Virus Disease, Springer-Verlag.","DOI":"10.1007\/978-3-662-01593-3"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(82)91871-2","article-title":"Marburg-virus disease in Kenya","volume":"1","author":"Smith","year":"1982","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00705-010-0814-x","article-title":"Proposal for a revised taxonomy of the family filoviridae: Classification, names of taxa and viruses, and virus abbreviations","volume":"155","author":"Kuhn","year":"2010","journal-title":"Arch. Virol."},{"key":"ref_5","first-page":"23","article-title":"Lessons from the marburg virus epidemic in Durba, Democratic Republic of the Congo (1998\u20132000)","volume":"60","author":"Zeller","year":"2000","journal-title":"Med. Trop. (Mars)"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0163-4453(03)00122-1","article-title":"Organisation of health care during an outbreak of Marburg haemorrhagic fever in the Democratic Republic of Congo, 1999","volume":"48","author":"Colebunders","year":"2004","journal-title":"J. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.00069-06","article-title":"Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola","volume":"80","author":"Towner","year":"2006","journal-title":"J. Virol."},{"key":"ref_8","first-page":"579","article-title":"Repeated outbreaks of viral hemorrhagic fevers in Uganda","volume":"12","author":"Mbonye","year":"2012","journal-title":"Afr. health sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/rmv.661","article-title":"Prospects for immunisation against Marburg and Ebola viruses","volume":"20","author":"Geisbert","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Swearengen, J.R. (2005). Biodefense: Research Methodology and Animal Models, Taylor & Francis Group.","DOI":"10.1201\/9781420038118"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4161\/hv.7.6.15398","article-title":"Filovirus vaccines","volume":"7","author":"Bradfute","year":"2011","journal-title":"Hum. Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3201\/eid0805.010284","article-title":"Evaluation in nonhuman primates of vaccines against Ebola virus","volume":"8","author":"Geisbert","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0264-410X(01)00353-X","article-title":"Marburg virus vaccines, comparing classical and new approaches","volume":"20","author":"Hevey","year":"2002","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tim.2014.12.005","article-title":"A race for an Ebola vaccine: Promises and obstacles","volume":"23","author":"Cooper","year":"2015","journal-title":"Trends Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/viro.1998.9367","article-title":"Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates","volume":"251","author":"Hevey","year":"1998","journal-title":"Virology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1128\/JVI.03361-12","article-title":"Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus","volume":"87","author":"Herbert","year":"2013","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10386","DOI":"10.1128\/JVI.00594-10","article-title":"Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates","volume":"84","author":"Geisbert","year":"2010","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1128\/JVI.00105-07","article-title":"Successful topical respiratory tract immunization of primates against Ebola virus","volume":"81","author":"Bukreyev","year":"2007","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Blaney, J.E., Marzi, A., Willet, M., Papaneri, A.B., Wirblich, C., Feldmann, F., Holbrook, M., Jahrling, P., Feldmann, H., and Schnell, M.J. (2013). Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003389"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1086\/520583","article-title":"Ebola virus-like particle-based vaccine protects nonhuman primates against lethal ebola virus challenge","volume":"196","author":"Warfield","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14760584.7.4.417","article-title":"Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses","volume":"7","author":"Swenson","year":"2008","journal-title":"Expert Rev. Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/157016210791208659","article-title":"Virus-like particles as particulate vaccines","volume":"8","author":"Buonaguro","year":"2010","journal-title":"Curr. HIV Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","article-title":"Vaccination with virus-like particles protects mice from lethal infection of rift valley fever virus","volume":"385","author":"Naslund","year":"2009","journal-title":"Virology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/infdis\/174.Supplement_1.S88","article-title":"Virus-like particles as a rotavirus subunit vaccine","volume":"174","author":"Conner","year":"1996","journal-title":"J. Infect Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1521-6616(03)00120-7","article-title":"Humoral, mucosal, and cellular immune responses to oral norwalk virus-like particles in volunteers","volume":"108","author":"Tacket","year":"2003","journal-title":"Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Roldao","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1084\/jem.20011500","article-title":"Lipid raft microdomains: A gateway for compartmentalized trafficking of Ebola and Marburg viruses","volume":"195","author":"Bavari","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","article-title":"Virus-like particles exhibit potential as a pan-filovirus vaccine for both ebola and Marburg viral infections","volume":"23","author":"Swenson","year":"2005","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1128\/JVI.02183-06","article-title":"Mapping of the VP40-binding regions of the nucleoprotein of Ebola virus","volume":"81","author":"Noda","year":"2007","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1128\/JVI.75.6.2660-2664.2001","article-title":"Protection from ebola virus mediated by cytotoxic t lymphocytes specific for the viral nucleoprotein","volume":"75","author":"Wilson","year":"2001","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Warfield, K.L., Dye, J.M., Wells, J.B., Unfer, R.C., Holtsberg, F.W., Shulenin, S., Vu, H., Swenson, D.L., Bavari, S., and Aman, M.J. (2014). Homologous and heterologous protection of nonhuman primates by Zaire and Sudan ebolavirus virus-like particles. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118881"},{"key":"ref_36","first-page":"140","article-title":"Lethal experimental infection of rhesus monkeys with ebola-Zaire (mayinga) virus by the oral and conjunctival route of exposure","volume":"120","author":"Jaax","year":"1996","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1089\/bsp.2004.2.186","article-title":"Marburg and Ebola viruses as aerosol threats","volume":"2","author":"Leffel","year":"2004","journal-title":"Biosecur. Bioterror."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1016\/j.vaccine.2004.01.063","article-title":"Marburg virus-like particles protect guinea pigs from lethal marburg virus infection","volume":"22","author":"Warfield","year":"2004","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0928-8244(03)00273-6","article-title":"Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein","volume":"40","author":"Swenson","year":"2004","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1086\/520612","article-title":"Filovirus-like particles produced in insect cells: Immunogenicity and protection in rodents","volume":"196","author":"Warfield","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/jcm.13.4.791-793.1981","article-title":"Plaque assay for Ebola virus","volume":"13","author":"Moe","year":"1981","journal-title":"J. Clin. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1128\/CVI.00467-09","article-title":"Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector","volume":"17","author":"Pratt","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vascn.2003.07.001","article-title":"The automated bioaerosol exposure system: Preclinical platform development and a respiratory dosimetry application with nonhuman primates","volume":"49","author":"Hartings","year":"2004","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Swearengen, J.R. (2006). Biodefense: Research Methodology and Animal Models, Taylor & Francis Group.","DOI":"10.1201\/9781420038118"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Stahl-Hennig, C., Eisenblatter, M., Jasny, E., Rzehak, T., Tenner-Racz, K., Trumpfheller, C., Salazar, A.M., Uberla, K., Nieto, K., and Kleinschmidt, J. (2009). Synthetic double-stranded rnas are adjuvants for the induction of t helper 1 and humoral immune responses to human Papillomavirus in rhesus macaques. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000373"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells require a systemic type I interferon response to mature and induce CD4+ TH1 immunity with poly ic as adjuvant","volume":"206","author":"Longhi","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Martins, K.A., Steffens, J.T., van Tongeren, S.A., Wells, J.B., Bergeron, A.A., Dickson, S.P., Dye, J.M., Salazar, A.M., and Bavari, S. (2014). Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089735"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/bsp.2011.0051","article-title":"Evaluation of perceived threat differences posed by filovirus variants","volume":"9","author":"Kuhn","year":"2011","journal-title":"Biosecur. Bioterror."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/jama.2014.9757","article-title":"Largest-ever Ebola outbreak still simmering in West Africa","volume":"312","author":"Stephenson","year":"2014","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1126\/science.1259657","article-title":"Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak","volume":"345","author":"Gire","year":"2014","journal-title":"Science"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/4\/94\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:21:57Z","timestamp":1760210517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/4\/94"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,8]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4]]}},"alternative-id":["v8040094"],"URL":"https:\/\/doi.org\/10.3390\/v8040094","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,8]]}}}